Modulating the histamine H4 receptor enhances anti-tumor efficacy in a mouse model of breast cancer
-
By
-
Ramiro Vázquez
-
Paula Saibene
-
Maria Emilia Boix
-
Mariano Maio
-
Gabriela Salamone
-
Luciana Balboa
-
Mónica Vermeulen
-
April 21, 2026
-
Clinical Scorecard: Modulating the histamine H4 receptor enhances anti-tumor efficacy in a mouse model of breast cancer
At a Glance
| Category | Detail |
|---|
| Condition | Breast Cancer |
| Key Mechanisms | Histamine H4 receptor modulation affects tumor cell proliferation and immune response. |
| Target Population | Women with breast cancer, particularly those with aggressive subtypes like triple-negative breast cancer. |
| Care Setting | Preclinical research using murine models. |
Key Highlights
- H4R blockade inhibits tumor cell proliferation and migration.
- Increased recruitment of CD8+ lymphocytes observed with H4R antagonist treatment.
- Histamine's role in tumor progression is context-dependent, influenced by the tumor microenvironment.
Guideline-Based Recommendations
Diagnosis
- Further research needed to establish HDC and H4R as prognostic markers.
Management
- Consider H4R antagonists as potential therapeutic agents in breast cancer treatment.
Monitoring & Follow-up
- Monitor immune response changes in tumor microenvironment following H4R modulation.
Risks
- Potential for conflicting effects of histamine depending on receptor involvement.
Patient & Prescribing Data
Women diagnosed with breast cancer, especially those with triple-negative subtypes.
H4R antagonists may enhance anti-tumor immunity and reduce tumor growth.
Clinical Best Practices
- Evaluate the immune microenvironment when considering histamine-related therapies.
- Conduct further studies to clarify the role of H4R in breast cancer progression.
References
